In this study we aimed to determine whether intra‐tumor heterogeneity of PR influences the long‐term risk of distant recurrence and endocrine therapy benefit in premenopausal women with ER‐positive disease, using the Stockholm tamoxifen trial (STO‐5) which has now reached 20 years of complete follow‐up. This evidence concerns the gene PGR and neoplasm.